Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma.
Haibo SunThomas G MartinJohn MarraDenice KongJonathon KeatsSandrine MacéMarielle ChironJeffrey L WolfJeffrey M VenstromRaja RajalingamPublished in: Journal for immunotherapy of cancer (2022)
NCT01749969.